Valuation: NEOVACS

Market Cap 4.09T 4.66T 3.76T 3.51T 6.61T 4L 6.75T 45.27T 17.54T 2L 17.49T 17.11T 8L P/E 2023 *
-
P/E 2024 -
Enterprise Value -2L -2L -2L -2L -3L -2.18Cr -3L -22.25L -9L -1.07Cr -9L -8L -3.72Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
0.01%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Chairman - -
Director/Board Member - 01/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 2L
+3.08%+6.47%-0.25%+5.47% 4.72TCr
+0.12%+10.45%+408.29%+600.97% 3.98TCr
+5.17%+9.47%+24.96%-9.60% 3.22TCr
+2.02%+4.91%+18.59%+63.06% 3.17TCr
+0.69%+1.04%+14.23%+30.86% 2.46TCr
+0.40%+12.51% - - 1.66TCr
+2.64%+6.00%+69.30%+126.33% 1.51TCr
-0.15%+2.15%+12.64%+17.71% 1.37TCr
+0.77%+10.67%+17.58%-30.04% 1.33TCr
Average +1.37%+6.99%+70.67%+100.60% 2.6TCr
Weighted average by Cap. +1.93%+7.03%+89.34%+130.43%

Financials

2023 2024
Net sales 5L 6L 5L 5L 9L 5.78Cr 9L 59.05L 22.88L 2.84Cr 22.81L 22.32L 9.87Cr 4L 5L 4L 4L 7L 4.7Cr 7L 48.04L 18.61L 2.31Cr 18.56L 18.16L 8.03Cr
Net income -87.43L -99.58L -80.48L -74.99L -1.41Cr -95Cr -1.44Cr -9.68Cr -3.75Cr -46Cr -3.74Cr -3.66Cr -161.74Cr -3.29Cr -3.75Cr -3.03Cr -2.82Cr -5.32Cr -356.41Cr -5.43Cr -36Cr -14Cr -174.95Cr -14Cr -14Cr -608.86Cr
Net Debt -2L -3L -2L -2L -4L -2.56Cr -4L -26.18L -10.14L -1.26Cr -10.11L -10L -4.37Cr -2L -2L -2L -2L -3L -2.22Cr -3L -22.7L -9L -1.09Cr -9L -9L -3.79Cr
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-